RATIONALE: Food allergy (FA) affects an increasing proportion of children in the US and other developed countries for reasons that remain largely unknown. A deeper understanding of pathogenic mechanisms active in FA may lead to much needed diagnostic and prognostic biomarkers of disease and improved treatment options. METHODS: Children with asthma alone, children with FA alone, children with both FA and asthma as well as healthy pediatric controls were recruited in the Allergy clinic at Boston Children's Hospital. Mass spectrometry-based untargeted metabolomic profiling was performed on serum samples (n535 for FA or asthma alone and FA/asthma; n520 for controls) looking at global metabolism. RESULTS: Untargeted metabolomic analysis revealed differential profiles of altered metabolites in patients' groups. In comparison to both controls and children with asthma, FA was uniquely associated with a marked decrease in sphingolipids -in particular sphingomyelins and ceramides -as well as lysophospholipids. Among atopic children, differences in aromatic amino acid metabolism and metabolism of secondary bile acids were observed between food allergic and asthmatic children. Among children with FA, the metabolomic profile of those with asthma was indistinguishable from that of children without asthma. CONCLUSIONS: Both unique and shared metabolomic alterations were detected in children with FA, asthma, or both, likely reflecting overlapping but distinct mechanisms and environmental influences operative in these disorders. Lower levels of sphingolipids and ceramides observed in food allergic children may affect the interplay between microbiota and immune cell subsets in the gut, including iNKT cells. RATIONALE: Egg-allergic, baked-egg tolerant children incorporating baked-egg products (BEPs) into their diets may accelerate development of tolerance to all forms of egg compared to strict egg-elimination diets. We investigated whether egg-OIT and BEPs had comparable efficacy in establishing desensitization and SU to unbaked-egg. METHODS: 52 baked-egg tolerant subjects (3.5-16.8 y/o) identified by baked-and unbaked-egg DBPCFCs were randomized to receive BEPs (;2g baked-egg protein daily; N528) or egg-OIT (2.5g egg-white protein daily; N524 [Egg OIT-Randomized]) for up to 2-years; 40 additional subjects intolerant to baked-egg were assigned to egg-OIT [Egg OITAssigned]. Desensitization-and SU-DBPCFCs (cumulative dose57444mg egg-white protein) were performed after 2-years of treatment. RESULTS: Egg-OIT-treated baked-egg tolerant children were significantly more likely to develop desensitization (87.0% vs 22.2%, p<0.0001) and SU (43.5% vs 11.1%; p50.009) at 2 years than BEPs-treated subjects, whereas egg-OIT in baked-egg tolerant versus baked-egg intolerant children revealed differences in SU (43.5% vs 17.9%; p50.031) but not desensitization (87.0% vs 69.2%, p50.15). In Year-1, the median percent of doses/subject with any adverse reaction was 2.8% for Baked-egg, 3.9% for Egg-OIT-Randomized and 12.6% for Egg-OIT-Assigned subjects; most dosing symptoms were mild. Dosing compliance was ;90% of expected doses in BEPs-treated versus >95% for both egg-OIT groups. Eight (28.5%) BEPs-treated subjects withdrew compared to 3 (12.5%) Egg-OIT-Randomized and 7 (17.5%) Egg OIT-Assigned subjects. Egg OIT-Randomized subjects experienced significantly greater increases in egg-white and egg-component IgG4 and IgG4:IgE ratios at Year-1 than the BEPs-treated group. CONCLUSIONS: Egg-OIT appears superior to BEPs in inducing both desensitization and SU in egg-allergic, baked-egg tolerant children.
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Intralymphatic Immunotherapy for Peanut Allergy: A pilot study of three patients Ronald A. Simon, MD FAAAAI, and Jennifer A. Namazy, MD FAAAAI; Scripps Clinic, San Diego, CA. RATIONALE: Previous studies have evaluated the safety and efficacy of intralymphatic immunotherapy for the treatment of grass pollen, dust mite and cat induced rhinoconjunctivitis. In this study we sought to assess the efficacy and safety of intralymphatic immunotherapy for the treatment of food allergy, specifically peanut.
METHODS:
In an open pilot investigation three subjects with a history of peanut allergy , strong + prick skin tests and high levels of peanut specific IgE and two with positive single blinded peanut challenge were treated with three intralymphatic inguinal injections of peanut extract. Pretreatment protocol was used to reduce risk of systemic side effects. Subjects received three injections of peanut extract at one month intervals into a superficial inguinal lymph node using ultrasound guidance. Post treatment outcomes were assessed with prick skin test, peanut specific IgE and single blinded peanut challenge. RESULTS: Each of the three subjects experienced systemic reactions to one or more of the intralymphatic immunotherapy doses, however when used with a pretreatment protocol of oral antihistamines, short acting beta agonist , leukotriene modifiers, and oral corticosteroid, none of the reactions were life threatening. All three subjects were able to tolerate peanut after the treatment. All three also displayed a reduction in prick skin test to peanut extract and two subjects displayed an increase in peanut specific IgE. CONCLUSIONS: Intralymphatic immunotherapy with peanut extract for the treatment of peanut allergy appears to induce tolerance. When performed with a pretreatment medication protocol, severe adverse events may be avoided.
